Product Information
GABAPENTIN 400 MG CAPSULE is a generic product labeled by McKesson, priced at $0.0410 per EA under NDC 63739090410. Its NADAC has been published 222 times since Apr 6, 2022.
FDA first approved this application on Dec 17, 2010. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
400 mg/1
Manufacturer
McKessonNDC
63739090410
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
6/17/2026
Active Ingredients
GABAPENTINApproval Type
Generic (ANDA)
FDA Application
ANDA090858FDA Approved
12/17/2010
TE Code
AB
On Market Since
7/15/2021
Pharmacological Classes
Price Statistics
The NADAC for GABAPENTIN 400 MG CAPSULE has been published 222 times since Apr 6, 2022, and over the history we have for it it has declined 33.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0410 per EA |
|---|---|
| All-time high | $0.0631 (Nov 16, 2022) |
| All-time low | $0.0396 (Apr 22, 2026) |
| 52-week high | $0.0434 |
| 52-week low | $0.0396 |
| Median price | $0.0525 |
| Average price | $0.0508 |
| Largest weekly change | +23.4% (Aug 21, 2024) |
| Weeks tracked | 222 |
| Tracking since | Apr 6, 2022 |
1W
N/A
1M
N/A
3M
N/A
6M
+3.1%
1Y
-5.4%
3Y
-32.4%
5Y
N/A
All
-33.8%
Last surveyed Jul 1, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 14 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
McKesson manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Gabapentin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GABAPENTIN 400 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for GABAPENTIN 400 MG CAPSULE, manufactured by McKesson, is $0.0410 per EA (NDC 63739090410), effective Jul 1, 2026.
How has the price of GABAPENTIN 400 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for GABAPENTIN 400 MG CAPSULE has declined 33.8%. It has been tracked across 222 weekly CMS publications since Apr 6, 2022.
What are the highest and lowest recorded NADAC prices for GABAPENTIN 400 MG CAPSULE?
Since Apr 6, 2022, the NADAC for GABAPENTIN 400 MG CAPSULE has ranged from a low of $0.0396 (Apr 22, 2026) to a high of $0.0631 (Nov 16, 2022), with a median of $0.0525 per EA.
Are there cheaper alternatives to GABAPENTIN 400 MG CAPSULE?
14 manufacturers publish a NADAC-priced product with the same active ingredient and strength as GABAPENTIN 400 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures GABAPENTIN 400 MG CAPSULE?
GABAPENTIN 400 MG CAPSULE (NDC 63739090410) is labeled by McKesson, and CMS classifies it as a generic product.